Revumenib after stem cell transplant for acute leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a drug called revumenib to help keep leukemia from coming back after a stem cell transplant. It is for people with specific genetic types of acute leukemia who have recently had or will soon have a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 2 or older
- You have acute leukemia (AML, ALL, or a mixed type) with certain gene changes like NPM1 or KMT2A
- You are either scheduled for a stem cell transplant within the next month or have had one within the last 4 months
- After transplant, you must be in remission, have recovered blood counts, and have no major organ problems or severe graft-versus-host disease
- You must be able to take a particular antifungal medication (like voriconazole or posaconazole)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests revumenib, a targeted medicine, to treat acute leukemia that has come back or hasn’t fully gone away. It may help people whose leukemia has specific gene changes (like KMT2A or NPM1) by trying to better control the cancer.
This trial tests two experimental drugs, revumenib and mezigdomide, for people with acute leukemia that has certain genetic changes (NPM1, KMT2A, or NUP98) and has come back or not responded to prior treatment. The goal is to see if this combination can help control the leukemia.
This trial tests adding ruxolitinib to standard drugs (tacrolimus and methotrexate) to prevent graft-versus-host disease in children and young adults undergoing a stem cell transplant for acute leukemia or myelodysplastic syndrome. The goal is to lower the risk of GVHD and improve transplant outcomes.
This study tests a new targeted pill (a menin inhibitor) taken after a stem cell transplant to help keep AML from coming back. It's for people with certain genetic markers in their leukemia who are already planning a transplant.
This trial tests a new drug called revumenib combined with a strong chemotherapy regimen (7+3) and midostaurin for people with newly diagnosed AML that has specific gene mutations (FLT3 and NPM1). The goal is to see if this combination works better than standard treatments.
This study tests a combination of two medicines, blinatumomab and revumenib, for people with a specific genetic form of leukemia (KMT2A). The goal is to see if adding revumenib helps the treatment work better and keeps the cancer in remission.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.